1-{[(1S,3R,6S)-2,1'-spirocyclopropane(bicyclo[2.2.1]heptane)-1'-norbornylmethyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one | 919482-40-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 1-{[(1S,3R,6S)-2,1'-spirocyclopropane(bicyclo[2.2.1]heptane)-1'-norbornylmethyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
• 英文别名: 3-{1-[(1R,3S,4S)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one；3-{1-[(1R,3S,4S)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidin-4yl}-1,3-dihydro-2H-benzimidazol-2-One；3-[1-[[(1S,2S,4R)-spiro[bicyclo[2.2.1]heptane-3,1'-cyclopropane]-2-yl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one
• CAS: 919482-40-9
• 化学式: C₂₂H₂₉N₃O
• 分子量: 351.492
• InChiKey: WOXZNJYICSMFDO-JZXOWHBKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-{[(1S,3R,6S)-2,1'-spirocyclopropane(bicyclo[2.2.1]heptane)-1'-norbornylmethyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one 、 (R)-(-)-对甲基苯磺酸-2,2-二甲基-1,3-二氧戊环基-4-甲酯 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 以73%的产率得到1-[(4R)-2,2-dimethyl-1,3-dioxolane-4-methyl]-3-{[(1S,3R,6S)-2,1'-spirocyclopropane(bicyclo[2.2.1]heptane)-1'-norbornylmethyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
  参考文献：
  名称：

  Identification of an Orally Active Opioid Receptor-like 1 (ORL1) Receptor Antagonist 4-{3-[(2R)-2,3-Dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1′-cyclopropan]-3-ylmethyl]piperidine as Clinical Candidate

  摘要：

  Our efforts to optimize prototype opioid receptor-like I (ORL1) antagonist 1 led to the discovery of 4-{3-[(2R)-2, 3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine 10. 10 showed potent ORL1 antagonistic activity, excellent selectivity over other opioid receptors, and in vivo efficacy after oral dosing. Currently clinical trials of 10 are underway.

  DOI：

  10.1021/jm900581g
• 作为产物：
  描述：

  1-(methylsulfonyl)-3-{1-[(1R,3S,4S)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 生成 1-{[(1S,3R,6S)-2,1'-spirocyclopropane(bicyclo[2.2.1]heptane)-1'-norbornylmethyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
  参考文献：
  名称：

  N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives

  摘要：

  该发明提供了由式(I)表示的化合物，其中R代表二羟基取代的C1-C6烷基基团，Cy代表一个可选择取代的C6-C10双环或三环脂肪环碳环基团。这些化合物作为痛觉受体拮抗剂，例如，可用作缓解对麻醉镇痛药的耐受性、对麻醉镇痛药的依赖或成瘾的药物；镇痛增强剂；抗肥胖或食欲抑制剂；治疗或预防认知障碍和失忆症/健忘症的药物；治疗发育性认知异常的药物；治疗精神分裂症的药物；治疗神经退行性疾病的药物；抗抑郁或治疗情感障碍的药物；治疗或预防尿崩症的药物；治疗或预防多尿症的药物；以及治疗低血压等的药物。

  公开号：

  US20070015792A1

文献信息

• US7300947B2
  申请人：——

  公开号：US7300947B2

  公开（公告）日：2007-11-27
• N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
  申请人：Hashimoto Masaya

  公开号：US20070015792A1

  公开（公告）日：2007-01-18

  The invention provides the compounds represented by the formula (I) in which, R stands for a dihydroxy-substituted C 1 -C 6 alkyl group, and Cy stands for an optionally substituted C 6 -C 10 bi- or tri-cyclic aliphatic carbocyclic group. These compounds act as nociceptin receptor antagonist, and are useful, for example, as relievers against tolerance to narcotic analgesic, dependence on narcotic analgesic or addiction; analgesic enhancers; antiobestic or appetite suppressors; treating or prophylactic agents for cognitive impairment and dementia/amnesia; agents for treating developmental cognitive abnormality; remedy for schizophrenia; agents for treating neurodegenerative diseases; anti-depressant or treating agents for affective disorder; treating or prophylactic agents for diabetes insipidus; treating or prophylactic agents for polyuria; and remedy for hypotension and the like.

  该发明提供了由式(I)表示的化合物，其中R代表二羟基取代的C1-C6烷基基团，Cy代表一个可选择取代的C6-C10双环或三环脂肪环碳环基团。这些化合物作为痛觉受体拮抗剂，例如，可用作缓解对麻醉镇痛药的耐受性、对麻醉镇痛药的依赖或成瘾的药物；镇痛增强剂；抗肥胖或食欲抑制剂；治疗或预防认知障碍和失忆症/健忘症的药物；治疗发育性认知异常的药物；治疗精神分裂症的药物；治疗神经退行性疾病的药物；抗抑郁或治疗情感障碍的药物；治疗或预防尿崩症的药物；治疗或预防多尿症的药物；以及治疗低血压等的药物。
• Identification of an Orally Active Opioid Receptor-like 1 (ORL1) Receptor Antagonist 4-{3-[(2<i>R</i>)-2,3-Dihydroxypropyl]-2-oxo-2,3-dihydro-1<i>H</i>-benzimidazol-1-yl}-1-[(1<i>S</i>,3<i>S</i>,4<i>R</i>)-spiro[bicyclo[2.2.1]heptane-2,1′-cyclopropan]-3-ylmethyl]piperidine as Clinical Candidate
  作者：Atsushi Satoh、Takeshi Sagara、Hiroki Sakoh、Masaya Hashimoto、Hiroshi Nakashima、Tetsuya Kato、Yasuhiro Goto、Sayaka Mizutani、Tomoko Azuma-Kanoh、Takeshi Tani、Shoki Okuda、Osamu Okamoto、Satoshi Ozaki、Yoshikazu Iwasawa、Hisashi Ohta、Hiroshi Kawamoto

  DOI：10.1021/jm900581g

  日期：2009.7.23

  Our efforts to optimize prototype opioid receptor-like I (ORL1) antagonist 1 led to the discovery of 4-3-[(2R)-2, 3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine 10. 10 showed potent ORL1 antagonistic activity, excellent selectivity over other opioid receptors, and in vivo efficacy after oral dosing. Currently clinical trials of 10 are underway.